Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pasithea Therapeutics Corp. (KTTA)

0.4   -0.03 (-6.93%) 03-24 16:00
Open: 0.4001 Pre. Close: 0.4298
High: 0.4283 Low: 0.3911
Volume: 53,536 Market Cap: 12(M)

Technical analysis

as of: 2023-03-24 4:27:35 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.61     One year: 0.71
Support: Support1: 0.39    Support2: 0.32
Resistance: Resistance1: 0.52    Resistance2: 0.61
Pivot: 0.45
Moving Average: MA(5): 0.42     MA(20): 0.46
MA(100): 0.72     MA(250): 0.96
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 22.1     %D(3): 26.2
RSI: RSI(14): 27.3
52-week: High: 1.53  Low: 0.39
Average Vol(K): 3-Month: 88 (K)  10-Days: 27 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KTTA ] has closed above bottom band by 3.0%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.43 - 0.43 0.43 - 0.43
Low: 0.39 - 0.39 0.39 - 0.39
Close: 0.4 - 0.4 0.4 - 0.4

Company Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Headline News

Thu, 02 Mar 2023
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to ... - GlobeNewswire

Tue, 24 Jan 2023
PASITHEA THERAPEUTICS CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) -

Wed, 18 Jan 2023
Pasithea Therapeutics Signs CMC Development and Manufacturing ... - BioSpace

Mon, 12 Dec 2022
Pasithea Therapeutics Announces Comprehensive Settlement ... - GlobeNewswire

Tue, 06 Dec 2022
Pasithea Therapeutics to Present at Annual Meeting of the Antibody ... - GlobeNewswire

Mon, 28 Nov 2022
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 29 (M)
% Held by Insiders 1.846e+007 (%)
% Held by Institutions 23.5 (%)
Shares Short 170 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 481.1
Return on Equity (ttm) -20.7
Qtrly Rev. Growth 260910
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 52920
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.